These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7413661)

  • 21. Structure and anticoagulant properties of sulfated glycosaminoglycans from primitive Chordates.
    Pavão MS
    An Acad Bras Cienc; 2002 Mar; 74(1):105-12. PubMed ID: 11960179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of heparin and a semi-synthetic heparin analogue, A73025. II. Some effects on platelet function.
    Michalski R; Lane DA; Kakkar VV
    Br J Haematol; 1977 Oct; 37(2):247-56. PubMed ID: 603758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipolysis generates platelet dysfunction after in vivo heparin administration.
    Muriithi EW; Belcher PR; Day SP; Chaudhry MA; Caslake MJ; Wheatley DJ
    Clin Sci (Lond); 2002 Oct; 103(4):433-40. PubMed ID: 12241544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).
    Mikhailidis DP; Fonseca VA; Barradas MA; Jeremy JY; Dandona P
    Br J Clin Pharmacol; 1987 Oct; 24(4):415-24. PubMed ID: 3689624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Sulfation and Molecular Weight on Anticoagulant Activity of Dextran.
    Drozd NN; Logvinova YS; Torlopov MA; Udoratina EV
    Bull Exp Biol Med; 2017 Feb; 162(4):462-465. PubMed ID: 28243911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation and pharmacological activities of heparin and other sulfated mucopolysaccharides from thymus.
    Straus AH; Nader HB; Bianchini P; Osima B
    Biochem Pharmacol; 1981 May; 30(10):1077-83. PubMed ID: 6455123
    [No Abstract]   [Full Text] [Related]  

  • 28. Influence of proteoglycans (PG) and glycosaminoglycans (GAG) on ADP-, collagen- and thrombin-induced platelet aggregation.
    Klein K; Sinzinger H; Silberbauer K; Stachelberger H; Leithner C
    Artery; 1980; 8(5):410-5. PubMed ID: 6783013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of oversulfated dermatan sulfate derivatives on platelet aggregation.
    Maaroufi RM; Giordano P; Triadou P; Tapon-Bretaudière J; Dautzenberg MD; Fischer AM
    Thromb Res; 2007; 120(4):615-21. PubMed ID: 17222891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effect of high affinity heparin and low affinity heparin on methylene blue titration.
    Villanueva GB; Danishefsky I
    Thromb Res; 1981 Jan 1-15; 21(1-2):191-9. PubMed ID: 6453435
    [No Abstract]   [Full Text] [Related]  

  • 31. Heparin lysolecithin, and platelet function.
    Joist JH; Mustard JF
    Adv Exp Med Biol; 1975; 52():255-61. PubMed ID: 1124700
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of heparin and related glycosaminoglycans (GAGs) on thrombin-induced platelet aggregation and release.
    Cofrancesco E; Colombi M; Manfreda M; Pogliani EM
    Haematologica; 1988; 73(6):471-5. PubMed ID: 3148509
    [No Abstract]   [Full Text] [Related]  

  • 33. Glycosaminoglycans and lipoprotein metabolism: an overview.
    Ghiselli GC; Catapano AL
    Pharmacol Res Commun; 1979 Jul; 11(7):571-83. PubMed ID: 388469
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of heparin on the vascular distribution of *I-antithrombin III isoforms in rabbits.
    Carlson TH
    Thromb Res; 1989 Aug; 55(4):471-80. PubMed ID: 2814938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New data on heparin (a review)].
    Bychkov SM
    Vopr Med Khim; 1981; 27(6):726-36. PubMed ID: 7039095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Thrombosis induced by homocysteine does not depend on platelet aggregation or heparin cofactor's antithrombin activity].
    Zhang L; Zhang G
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):309-12, 340. PubMed ID: 12080632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein-lipase activation by an extractive heparinoid (glucuronoglucosaminoglycan).
    Avogaro P; Belussi F
    Pharmacol Res Commun; 1977 Apr; 9(4):391-6. PubMed ID: 866377
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of drugs used in the treatment of thrombotic and hemorrhagic conditions on the erythrocyte aggregation].
    Lakin KM; Ovnatanova MS
    Kardiologiia; 1977 May; 17(5):79-83. PubMed ID: 886757
    [No Abstract]   [Full Text] [Related]  

  • 39. In vivo release of anti-Xa clotting activity by a heparin analogue.
    Thomas DP; Barrowcliffe TW; Merton RE; Stocks J; Dawes J; Pepper DS
    Thromb Res; 1980 Mar; 17(6):831-40. PubMed ID: 6773178
    [No Abstract]   [Full Text] [Related]  

  • 40. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans.
    Yamagishi R; Niwa M; Kondo S; Sakuragawa N; Koide T
    Thromb Res; 1984 Dec; 36(6):633-42. PubMed ID: 6084876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.